The GLP-1 Face: How to Restore Volume and Lift After Rapid Weight Loss
What GLP-1 Medications Do to the Face
The results that GLP-1 receptor agonists produce for weight management are genuinely significant. Medications in this class, including semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), can produce 15 to 25 percent total body weight loss in many patients, often within six to twelve months. For patients who have struggled with weight for years, this is life-changing.
What many patients are not prepared for is what happens to the face during that process.
Fat is distributed throughout the body, including in the face. Facial fat pads sit at specific depths in the cheeks, temples, the area under the eyes, and along the jawline, and they provide the structural padding that gives a youthful face its fullness and definition. When the body loses fat rapidly, these facial fat pads deflate along with the fat deposits in the abdomen, thighs, and elsewhere. The problem is that the skin and soft tissue that used to sit over that fat does not always retract at the same pace. The result is a face that can look gaunt, hollow, or significantly older than it did before the weight loss began; sometimes even in patients who are now at a healthier body weight.
This phenomenon has been informally labeled "Ozempic face" in media coverage, though the effect is not unique to semaglutide. It is a predictable consequence of rapid, significant fat loss regardless of the method used to achieve it.
The changes typically manifest in a few specific ways: hollowing of the temples and cheeks, deepening of the nasolabial folds and marionette lines, loss of jawline definition, increased visibility of under-eye hollowing, and a descent of soft tissue that creates the appearance of jowling. Skin that has lost its underlying support structure may also appear crepey or loose, particularly along the lower face and neck.
Why This Is a Structural Problem, Not a Skin Problem
It is important to understand that the visible changes after GLP-1-related weight loss are primarily structural, which means they cannot be addressed by topical products or superficial treatments alone. A moisturizer cannot replace a deflated fat pad. A serum cannot reposition tissue that has descended.
The face ages in three dimensions: volume is lost from the deeper fat compartments and bone, the middle layer of skin loses density and collagen, and the surface shows the cumulative effect of that structural loss above it. Rapid weight loss compresses what might otherwise be a decade of gradual structural change into a period of months. Patients who are 45, 55, or 65 when they start a GLP-1 program may already have some degree of age-related volume loss, and the medication-driven fat loss accelerates what was already in progress.
Addressing these changes requires treatments that work at the structural level — replacing lost volume, restoring collagen density in the dermis, and mechanically supporting tissue that has descended. At Physician Skin Services, the most effective approach for the majority of GLP-1 patients experiencing facial changes is a combination of Sculptra and PDO thread lifts, sequenced appropriately for each patient.
How Sculptra Addresses Volume Loss After GLP-1 Weight Loss
Sculptra is a biostimulator, which means it does not simply add volume the way a traditional hyaluronic acid filler does. It stimulates the body's own collagen production by introducing poly-L-lactic acid microspheres into the deep dermis and subcutaneous tissue. Over a period of weeks to months, the skin responds to the presence of these microspheres by producing new collagen, which gradually rebuilds the structural density that the face has lost.
For GLP-1 patients, this mechanism is particularly well suited to the problem. The issue is not simply that the face needs filler in one area; it is that the collagen framework of the entire face has been destabilized. Sculptra addresses this broadly, rebuilding the foundational matrix in the cheeks, temples, jawline, and other areas that have been affected by the loss of fat pad support.
Because Sculptra works gradually, the results develop over two to three months and look completely natural. Patients do not walk out of an appointment looking dramatically different. Instead, over the weeks following treatment, the face quietly becomes fuller and firmer, the skin looks less hollow, and the overall structure of the face begins to reflect what the patient looked like before the weight loss affected the face.
Most patients in a GLP-1 recovery protocol at PSS require two to three Sculptra sessions, spaced four to six weeks apart, with results that continue to develop for six months and can last up to two years. This timeline works well for patients who are still actively losing weight, as treatments can be spaced to allow the face to stabilize before final assessment is made.
How PDO Threads Address Skin Laxity and Descent
While Sculptra rebuilds from within, PDO threads address the physical descent of soft tissue that rapid weight loss can accelerate. PDO (polydioxanone) threads are thin, absorbable sutures placed beneath the skin surface through a small needle or cannula entry point. They accomplish two things simultaneously: they provide an immediate mechanical lift by repositioning descended tissue, and they stimulate collagen production along their path as the thread gradually dissolves over the following months.
For GLP-1 patients, the areas most commonly treated with PDO threads include the lower face (jowl and jawline definition), the midface (cheek projection and nasolabial fold softening), and the neck. These are the areas where descended tissue is most visible and where a mechanical lift produces the most significant visible improvement.
The thread lift procedure at Physician Skin Services takes approximately 45 to 60 minutes. There is mild swelling and possible bruising for three to seven days. Most patients see the structural improvement clearly within two to three weeks as the initial swelling resolves. As the threads dissolve over three to six months, they leave behind a network of new collagen that maintains a degree of the lift even after the threads themselves are gone.
PDO Max threads, which PSS uses exclusively, are FDA-cleared and available in a variety of configurations for different treatment areas. Dr. Annika Crosby was featured in a webinar with PDO Max founder Giovanna McCarthy specifically on this topic, which speaks to the clinical depth behind PSS's approach to thread treatments.
Why These Two Treatments Work Better Together
Sculptra and PDO threads address different aspects of the same problem, which is why combining them produces more complete results than either treatment alone.
Sculptra rebuilds the volume and collagen density that has been lost — it addresses the deflation. PDO threads reposition the tissue that has descended because of that deflation — it addresses the gravitational change that followed. A patient who receives only Sculptra may regain fullness but still have visible jowling because the tissue has already descended and needs to be repositioned. A patient who receives only a thread lift may see good lifting but experience early recurrence because the structural foundation (collagen and volume) supporting that tissue has not been restored.
When both are used in sequence, Sculptra first (to rebuild the foundation) and PDO threads after (to lift and support the newly volumized tissue), the results are meaningfully more durable and more complete.
When Should GLP-1 Patients Consider Treatment?
This is a common question at PSS, and the answer depends on whether the patient is still actively losing weight. In general, we recommend that patients who are still in active weight loss wait until their weight has been relatively stable for two to three months before beginning a facial restoration protocol. Treating a face that is still changing significantly can result in over-treatment in some areas and under-treatment in others.
Patients who have reached their goal weight or maintenance phase are ideal candidates for evaluation. At that point, a comprehensive consultation allows us to assess the degree of volume loss, the extent of tissue descent, and the appropriate sequence and dosing of treatments.
It is also worth noting that GLP-1 medications are not going away. Many patients will be on these medications long-term for metabolic health. Facial restoration is becoming a standard part of the conversation for patients on these medications, and PSS is well positioned to guide that discussion.
Starting the Conversation at PSS
If you are on a GLP-1 medication and have noticed changes in your face — hollowing, jowling, a loss of the definition you had before — these are treatable changes. They are not simply a trade-off you have to accept. The structural tools to address them are available, clinically proven, and can be tailored to exactly what your face has experienced.
Call Physician Skin Services at 612-799-2135 or email Anita@PhysicianSkinServices.com to schedule a consultation at our St. Louis Park, Woodbury, or Edina locations. We will assess where the structural changes are most significant and build a plan that restores your face to match the healthier body you have worked hard to achieve.
